ChemotherapyFDA-approvedFirst-line

Carboplatin

How it works

Damages the DNA of cancer cells, preventing them from growing and dividing.

Cancer types

Efficacy

Carboplatin has been shown to improve survival rates and delay disease progression in ovarian cancer patients.

Side effects

Severe

This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.

Evidence from research

StudyCancer typeStageEfficacy
Testing Sacituzumab Tirumotecan in Advanced Lung CancerLung Cancerphase-3Source →
Testing a Combination Treatment for Early-stage Triple-negative Breast CancerBreast Cancerphase-2Source →
Researchers Investigate New Ovarian Cancer Treatment OptionsOvarian Cancerlab-studySource →
LINC00963 May Help Overcome Chemoresistance in Pancreatic CancerPancreatic Cancerlab-studySource →
Combining Medications Improves Lung Cancer Treatment for Some PatientsLung Cancerphase-3Combination therapy significantly prolonged median progression-free survival compared with monotherapy (19.78 vs 16.53 months; hazard ratio, 0.58; 95% confidence interval, 0.34-0.97).Source →
Adding Carboplatin to Chemotherapy Improves Outcomes in Early-Stage Triple-Negative Breast CancerBreast Cancerphase-3Adding carboplatin significantly improved disease-free survival (HR, 0.66; [95% CI, 0.44 to 0.97]; p = .034), distant disease-free survival (HR, 0.61 [95% CI, 0.38 to 0.98]; p = .040), and overall survival (HR, 0.39 [95% CI, 0.16 to 0.94]; p = .029).Source →
Testing Neoadjuvant Carboplatin for High-Risk Prostate Cancer with BRCA MutationsProstate Cancerphase-2Source →
Combining medications to treat advanced breast and ovarian cancerOvarian Cancerphase-1There were 3 major responses (1CR, 2PR) at DL1, and 1 CR at DL-1.Source →

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.